SemBioSys/Tasly Chinese transgenic plants JV for drugs and other products
This article was originally published in Scrip
Executive Summary
One of China's leading traditional Chinese medicine (TCM) manufacturers, Tasly Pharmaceuticals, has signed a deal with the Canadian biotechnology company SemBioSys to establish a joint venture in Tianjin for the development and commercialisation of drugs and other products 'manufactured' in transgenic plants.